Menu Content/Inhalt

Meet with us

BioMedical Asia & Drug Discovery World Asia
Singapore
March 16-19, 2010
and
AUTM Annual Meeting
March 18 - 20, 2010

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. We develop our products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

We independently fund the worldwide development of all of our products while providing expertise in preclinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

The sales turnover of our products through our licensees reached $2.6 billion in 2008.

 

News

09-Feb-2010
Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C -

04-Feb-2010
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer

07-Jan-2010
Pfizer and Debiopharm collaborate to co-develop investigational compound tremelimumab (CP-675,206) in advanced melanoma

09-Feb-2010
Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C -

04-Feb-2010
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer

07-Jan-2010
Pfizer and Debiopharm collaborate to co-develop investigational compound tremelimumab (CP-675,206) in advanced melanoma

09-Feb-2010
Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C -

04-Feb-2010
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer

07-Jan-2010
Pfizer and Debiopharm collaborate to co-develop investigational compound tremelimumab (CP-675,206) in advanced melanoma